AbbVie Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer’s Disease and Progressive Supranuclear Palsy

 

– Initiation of Phase 2 clinical trial programs in early Alzheimer’s disease and progressive supranuclear palsy (PSP) is part of ongoing commitment to investigate ABBV-8E12 and tau-focused approaches to delay disease progression
– ABBV-8E12 granted Fast Track Designation from the U.S. Food and Drug Administration for PSP
– Orphan Drug Designations received from the U.S. Food and Drug Administration and European Medicines Agency for ABBV-8E12 in PSP

NORTH CHICAGO, Ill., Jan. 25, 2017 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced the start of two Phase 2 clinical trial programs to evaluate ABBV-8E12, an investigational anti-tau antibody, in patients with early Alzheimer’s disease and progressive supranuclear palsy (PSP). In recognition of the lack of treatment options


Read More →

C2N Diagnostics Reports Phase 1 Study Results of C2N-8E12 (ABBV-8E12) – Anti-Tau Antibody – in Subjects with Progressive Supranuclear Palsy

  • Clinical Investigator, Dr. Diana Kerwin, Presents Safety, Tolerability and PK Data at CTAD 2016 in Late-Breaking Oral Session
  • Results Demonstrate that ABBV-8E12 is Safe and Well Tolerated at Doses up to 50 mg/kg in Subjects with Progressive Supranuclear Palsy
  • Results are Guiding the Design of Phase 2 Studies in Subjects with Alzheimer’s Disease and Progressive Supranuclear Palsy

December 09, 2016

ST. LOUIS, MO – C2N Diagnostics today reported results from its Phase 1 study testing ABBV-8E12 (Formerly C2N-8E12) in patients with progressive supranuclear palsy (PSP). ABBV-8E12 is a humanized anti-tau monoclonal antibody currently under clinical investigation for the treatment of Alzheimer’s Disease and PSP, both progressive brain diseases currently lacking effective treatment options. Results from the first-in-human study were reported …
Read More →

C2N Diagnostics Completes Phase 1 Clinical Study of C2N-8E12 (ABBV-8E12) Among Individuals with Progressive Supranuclear Palsy

  • Achievement Represents the Final Milestone Under C2N’s “Part the Cloud” 2015 Translational Research Award from Alzheimer’s Association
  • Paves Way for Future, Longer-Term Clinical Studies Involving ABBV-8E12 Through Partnership with AbbVie

October 13, 2016

ST. LOUIS, MO – C2N Diagnostics today announced that it has successfully completed the final follow-up visit of the last subject enrolled into its Phase 1, randomized controlled clinical study testing C2N-8E12 (ABBV-8E12), an anti-tau antibody, in patients with progressive supranuclear palsy (PSP). The milestone marks the last of multiple achievements under C2N’s Part the Cloud (PTC) Translational Research Award, granted to C2N by the Alzheimer’s Association in 2015. Also, this is an important program milestone under …
Read More →

CurePSP Forms Subsidiary to Promote Clinical Trials

CurePSP has formed the new Patient Engagement Program (PEP) to help speed recruitment of eligible participants for industry-sponsored clinical trials, with the goal of finding treatments for degenerative brain diseases. Agreements have been reached with Bristol-Myers Squibb and AbbVie.

Read the press release.…
Read More →